"The USP of FORTIGEL(R) is the complete set of clinical data that provides testimony of its efficiency in the joint health segment," states Ghosh. "Meticulous research spanning three decades has yielded authentic evidence supporting FORTIGEL(R)'s effectiveness in regenerating joint cartilage, improving mobility and reducing pain."
At present, FORTIGEL(R) is the only ingredient to have a 'cartilage regeneration' claim with solid proof to back it up. The company is currently analysing the effect of FORTIGEL(R) against osteoporosis and represents the only viable natural treatment for the condition.
Gelita has maintained a competitive price for its breakthrough ingredient FORTIGEL(R). Despite being the pioneer in this segment, the company has chosen to follow a 'price-to-value' strategy, rather than a premium pricing model. The competitive pricing of FORTIGEL(R) has made it an affordable alternative to more expensive traditional osteoarthritis treatments.
The Frost and Sullivan Award for Joint Health Ingredient of the Year is presented to the company that has demonstrated excellence in new ingredient development and launch within its industry. The recipient company has shown tremendous innovation by launching a broad line of emerging products and technologies.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Gelita AG
GELITA AG is the world's leading manufacturer of gelatine and coll
'/>"/>
| SOURCE Frost & Sullivan Copyright©2008 PR Newswire. All rights reserved |